Wellington Shields Capital Management LLC Trims Stock Holdings in Edwards Lifesciences Co. (NYSE:EW)

Wellington Shields Capital Management LLC decreased its holdings in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) by 6.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 63,732 shares of the medical research company's stock after selling 4,100 shares during the quarter. Wellington Shields Capital Management LLC's holdings in Edwards Lifesciences were worth $4,718,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of EW. Versor Investments LP raised its stake in Edwards Lifesciences by 102.5% during the third quarter. Versor Investments LP now owns 4,455 shares of the medical research company's stock valued at $294,000 after purchasing an additional 2,255 shares in the last quarter. GSA Capital Partners LLP purchased a new stake in Edwards Lifesciences during the third quarter valued at $481,000. MQS Management LLC purchased a new stake in Edwards Lifesciences during the third quarter valued at $245,000. Oppenheimer & Co. Inc. raised its stake in Edwards Lifesciences by 3.9% during the third quarter. Oppenheimer & Co. Inc. now owns 38,186 shares of the medical research company's stock valued at $2,520,000 after purchasing an additional 1,441 shares in the last quarter. Finally, United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund raised its stake in shares of Edwards Lifesciences by 422.3% in the third quarter. United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund now owns 450,233 shares of the medical research company's stock valued at $29,711,000 after acquiring an additional 364,030 shares during the period. Hedge funds and other institutional investors own 79.46% of the company's stock.

Remove Ads

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on EW shares. Barclays increased their target price on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the company an "overweight" rating in a research note on Thursday, February 13th. Morgan Stanley increased their target price on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the company an "equal weight" rating in a research note on Wednesday, February 12th. Piper Sandler increased their target price on shares of Edwards Lifesciences from $70.00 to $73.00 and gave the company a "neutral" rating in a research note on Wednesday, February 12th. Evercore ISI cut their price target on shares of Edwards Lifesciences from $75.00 to $73.00 and set an "in-line" rating on the stock in a report on Wednesday, February 12th. Finally, Canaccord Genuity Group upped their price target on shares of Edwards Lifesciences from $68.00 to $71.00 and gave the stock a "hold" rating in a report on Thursday, February 13th. One analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and twelve have assigned a buy rating to the stock. Based on data from MarketBeat, Edwards Lifesciences currently has a consensus rating of "Hold" and a consensus price target of $79.95.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 9,500 shares of Edwards Lifesciences stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $67.96, for a total transaction of $645,620.00. Following the sale, the vice president now owns 46,936 shares of the company's stock, valued at $3,189,770.56. The trade was a 16.83 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Steven R. Loranger sold 5,739 shares of Edwards Lifesciences stock in a transaction on Friday, February 14th. The stock was sold at an average price of $76.42, for a total value of $438,574.38. Following the transaction, the director now owns 60,372 shares in the company, valued at approximately $4,613,628.24. This represents a 8.68 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 51,303 shares of company stock valued at $3,715,776. 1.29% of the stock is owned by company insiders.

Edwards Lifesciences Stock Performance

EW traded down $0.33 during trading on Tuesday, reaching $70.31. 3,702,921 shares of the company's stock were exchanged, compared to its average volume of 4,582,058. Edwards Lifesciences Co. has a 1 year low of $58.93 and a 1 year high of $96.12. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The stock has a market capitalization of $41.33 billion, a P/E ratio of 10.09, a price-to-earnings-growth ratio of 4.82 and a beta of 1.12. The company's fifty day simple moving average is $71.68 and its 200-day simple moving average is $70.34.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, topping analysts' consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. As a group, research analysts predict that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.